{
    "clinical_study": {
        "@rank": "93984", 
        "arm_group": [
            {
                "arm_group_label": "Human Placenta-Derived Cells PDA001 Intravenous Infusion", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous infusion of Human Placenta-Derived Cells PDA001 over the course of 2 hours."
            }, 
            {
                "arm_group_label": "Vehicle controlled placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intravenous infusion of  Vehicle Controlled Placebo over the course of 2 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the safety and efficacy of intravenous (IV) PDA001 infused every two weeks for up\n      to 5 total infusions in subjects with Crohn's disease who are refractory to one or more\n      standard Crohn's disease therapies."
        }, 
        "brief_title": "A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Crohns Disease", 
        "condition_browse": {
            "mesh_term": "Crohn Disease"
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, double-blind, placebo-controlled, dose-escalation study to study 3\n      cohorts of subjects with Crohn's Disease including (but not limited to) those with colonic\n      involvement.  Each cohort (n = 9) will include PDA001   treated subjects (n = 6) as well as\n      placebo (vehicle control) treated subjects (n = 3).  Cohorts will be enrolled sequentially,\n      beginning with the lowest dose cohort (1/4 unit PDA001) and progressing until the maximum\n      tolerated dose of IV PDA001 is determined."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022 Males and females 18 - 75 years of age at the time of signing the informed consent\n             document.\n\n               -  Minimum weight of subject is 40 kg at screening.\n\n               -  Subject must have inflammatory Crohn's Disease (CD) diagnosed at least 6 months\n                  but no greater than 15 years prior to treatment with Investigational Product\n                  (IP).\n\n               -  Subject must have confirmation of ongoing CD by ileocolonoscopy at screening.\n\n               -  Subject must have a Crohn's Disease Activity Index (CDAI) score \u2265 220 and \u2264 450\n                  as assessed between Visit 1 and Visit 2.\n\n        Exclusion Criteria:\n\n          -  Subject has any significant medical condition, laboratory abnormality, or psychiatric\n             illness that would prevent the subject from participating in the study including but\n             not limited to\n\n               -  Liver Function Tests Aspartate aminotransferase (AST) or Alanine\n                  aminotransferase (ALT) > 2.5 x the upper limit of normal at screening.\n\n               -  Serum creatinine concentration > 2.0 mg/dl at screening. Alkaline phosphatase >\n                  2.5 x the upper limit of normal at screening.\n\n               -  Bilirubin level > 2 mg/dL (unless subject has known Gilbert's disease).\n\n          -  Pregnant or lactating females.\n\n          -  Morbidly obese subjects Body Mass Index (BMI) > 35 at screening).\n\n          -  Subject has untreated chronic infection including Clostridium difficile toxin\n             positive at screening or treatment of any infection with antibiotics within 4 weeks\n             prior to dosing with IP (other than a treated urinary tract infection or drained\n             perianal abscess). Note: Stable doses of antibiotics used to treat Crohn's Disease\n             are allowed.\n\n          -  Subject has organic heart disease (eg, congestive heart failure), clinically\n             significant arrhythmia or clinically significant abnormal findings on\n             Electrocardiograms (ECG).\n\n          -  Subject has a history of other malignancies within 5 years (except basal cell\n             carcinoma of the skin that is surgically cured, remote history of cancer now\n             considered cured or positive Pap smear with subsequent negative follow up).\n\n          -  Subject has had a stricture of the bowel requiring hospitalization within 182 days\n             prior to treatment with IP.\n\n          -  Subject has had bowel surgery other than perianal (for example, fistulotomy, seton\n             placement, or abscess drainage) or previous abscess drainage within 182 days prior to\n             treatment with IP.\n\n          -  Subject has had any surgery within 28 days prior to treatment with IP.\n\n          -  Subject has a colostomy, ileostomy or ileal pouch anal anastomosis.\n\n          -  Subject has received an investigational agent \u2014an agent or device not approved by FDA\n             for marketed use in any indication\u2014within 90 days (or 5 half-lives, whichever is\n             longer) prior to treatment with investigational product.\n\n          -  Subject has received previous cell therapy.\n\n          -  Subject is expecting to have elective surgery at any time between Visit 1 (screening)\n             and Visit 7 (end of induction phase).\n\n          -  Subject has concurrent diagnosis of ulcerative colitis.\n\n          -  Subjects with protein C or S deficiency.\n\n          -  Subjects with prior history of thrombophlebitis or other pathological arterial or\n             venous thrombosis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01769755", 
            "org_study_id": "CCT-PDA001-CD-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Human Placenta-Derived Cells PDA001 Intravenous Infusion", 
                "description": "Cohort 1 Dose Level 1:  \u00bc unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.\nCohort 2 Dose Level 2:  \u00bd unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.\nCohort 3 Dose Level 3:  1 unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.", 
                "intervention_name": "PDA001", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Vehicle controlled placebo", 
                "description": "Cohort 1 Dose Level 1:  \u00bc unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.\nCohort 2 Dose Level 2:  \u00bd unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.\nCohort 3 Dose Level 3:  1 unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.", 
                "intervention_name": "Vehicle Controlled Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Crohn's disease", 
            "Fistula", 
            "Diarrhea", 
            "Colon", 
            "Stem cells"
        ], 
        "lastchanged_date": "March 17, 2014", 
        "location": [
            {
                "contact": {
                    "phone": "310-423-0035"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90048"
                    }, 
                    "name": "Cedars Sinai Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "303-724-7875"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "352-265-8971"
                }, 
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32608"
                    }, 
                    "name": "University of Florida"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "305-243-6405"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "585-922-3536"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14621"
                    }, 
                    "name": "Rochester General Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "513-475-7505"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267"
                    }, 
                    "name": "University of Cincinnati"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "216-844-7214"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Case Western University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "423-778-2982"
                }, 
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37403"
                    }, 
                    "name": "Erlanger Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37212"
                    }, 
                    "name": "Vanderbilt University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "713-798-7616"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Baylor College of Medicine"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "801-587-9092"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84132"
                    }, 
                    "name": "University of Utah"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "804-675-6789"
                }, 
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23249"
                    }, 
                    "name": "McGuire VA Medical Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease", 
        "overall_contact": {
            "email": "clinicaltrialdisclosure@celgene.com", 
            "last_name": "Associate Director Clinical Trial Disclosure", 
            "phone": "1-888-260-1599"
        }, 
        "overall_contact_backup": {
            "email": "loconnell@celgene.com", 
            "last_name": "Lynn Ann O'Connell", 
            "phone": "732-652-6146"
        }, 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "Steven Fischkoff, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of participants experiencing adverse events during the initial and extended follow-up periods", 
            "measure": "Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01769755"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate the time course of clinical efficacy of ascending doses of IV PDA001  versus placebo infused every other week for 8 weeks (5 total infusions) as measured by the Crohn's Disease Activity Index (CDAI) at each scheduled visit", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "Up to 1 year"
        }, 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}